Applying firm pressure for 1020 seconds after injecting and warming the medication to room temperature for 1530 minutes before use can also help reduce the likelihood of bruising
Tirzepatide (Mounjaro) is a related but distinct drug, a dual GIP/GLP-1 receptor agonist where the primary target is the GIP receptor with additional GLP-1 activity, making it pharmacologically different from pure GLP-1 drugs like semaglutide
Less common but more serious potential effects may include: Pancreatitis, gallbladder issues, kidney problems, and severe gastrointestinal symptoms
Ceriello A, Giugliano D, Quatraro A, Lefebvre PJ
[DOI] [PMC free article] [PubMed] [Google Scholar] Meier J
The medication is compounded by licensed 503A pharmacies and available in all 50 states without insurance or membership requirements